OraGen®, the first and only viable bone allograft, is now available for dental procedures

VIRGINIA BEACH, Va., Feb. 15, 2025 /PRNewswire/ -- LifeNet Health proudly announces the launch of OraGen®, the first viable dental bone allograft comprised of cryopreserved corticocancellous bone containing endogenous lineage-committed bone cells combined with demineralized bone matrix. This unique composition, the core of OraGen's innovation, delivers three essential properties for bone regeneration: osteogenicity, with lineage-committed bone cells that produce new bone; osteoconductivity, providing a biocompatible scaffold for cell attachment and growth; and osteoinduction, which stimulates bone repair through retained natural growth factors.

OraGen is designed for use in dental procedures, including sinus and ridge augmentation and repairing large defects in the mandible or maxilla. Building on the proven clinical success of LifeNet Health's advanced cellular allografts in bone repair and reconstruction, OraGen redefines the standard in dental tissue engineering—ushering in a new era of innovation and effectiveness in bone regeneration. ¹ It enables rapid new bone formation immediately after implantation and sustained growth over time.^2-4

OraGen sets a new standard for safety and convenience. It undergoes rigorous aseptic processing and features a proprietary cryopreservation method that maximizes cell viability by processing grafts within 72 hours—24 hours faster than competing products. OraGen also thaws in under five minutes, ensuring quick and easy preparation in clinical settings.

OraGen is now available in the U.S. through LifeNet Health's strategic partner, Salvin Dental Specialties, a trusted leader in dental surgical products. Tailored for advanced dental procedures, OraGen offers transformative potential for dental surgeons and their patients.

"We are thrilled to collaborate with Salvin Dental Specialties to introduce OraGen to the market," said Daniel Osborne, Chief Growth Officer at LifeNet Health. "This partnership reflects our commitment to delivering cutting-edge solutions that not only drive better patient outcomes but also advance the field of regenerative medicine. Together, we're not just facilitating healing; we're improving lives."

"Salvin Dental's exclusive distribution agreement with LifeNet Health for OraGen® demonstrates our unwavering commitment to providing the most comprehensive and innovative regenerative solutions to our customers," said Ken Serota, CEO of Young Innovations. "Salvin's enduring partnership with LifeNet Health has consistently focused on enhancing patient outcomes through a dedication to quality and service. Together, we look forward to empowering dental surgeons to improve their patients' quality of life."

LifeNet Health and Salvin Dental Specialties are committed to delivering these advancements with unmatched quality and exceptional customer support, strengthening their shared mission to elevate the standard of care in dental surgery.

About LifeNet Health
LifeNet Health is a global leader in regenerative medicine, providing a comprehensive range of transplant solutions from organ procurement to bio-implants and cellular therapies. LifeNet Health's mission is to improve the quality of human life by advancing medical possibilities in transplantation and research.

1. Gianulis E, Wetzell B, Scheunemann D, et al. Characterization of an advanced viable bone allograft with preserved native bone forming cells. Cell and tissue banking. 2022; (E-pub ahead of print). doi: 10.1007/s10561-022-10044-2.
2. Marschall, J. S., Davis, S. S., Jones, L., & Kushner, G. M. Are Cellular Bone Matrix Allografts a Viable Option for Mandibular Tissue Engineering and Reconstruction?  Journal of Oral and Maxillofacial Surgery. https://doi.org/10.1016/j.joms.2024.05.040.
3. Hall JF, McLean JB, Jones SM, Moore MA, Nicholson MD, Dorsch KA. Multilevel instrumented posterolateral lumbar spine fusion with an allogeneic cellular bone graft.  J Orthop Surg Res. 2019;14(1):372. doi:10.1186/s13018-019-1424-2
4. Clinical outcome and explant histology after using a cellular bone allograft in two-stage total hip arthroplasty. Shahrdar C, McLean J, Gianulis E, et al. J Orthop Surg Res. 2020;15(1):16. doi:10.1186/s13018-020-1542-x Article in Review

For more information: 
Doug Wilson
[email protected]
757-609-4468, office
757-348-2931, cell

SOURCE LifeNet Health